


## Camicinal hydrochloride

Cat. No.:	HY-10922A
CAS No.:	923565-22-4
Molecular Formula:	C <sub>25</sub> H <sub>34</sub> ClFN <sub>4</sub> O
Molecular Weight:	461.02
Target:	Motilin Receptor
Pathway:	GPCR/G Protein
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (216.91 mM; Need ultrasonic)  
DMSO : 100 mg/mL (216.91 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1691 mL	10.8455 mL	21.6910 mL
	5 mM	0.4338 mL	2.1691 mL	4.3382 mL
	10 mM	0.2169 mL	1.0846 mL	2.1691 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 100 mg/mL (216.91 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (5.42 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Camicinal hydrochloride (GSK962040 hydrochloride) is a small molecule, selective motilin receptor agonist with pEC<sub>50</sub> of 7.9.

#### IC<sub>50</sub> & Target

pEC<sub>50</sub>: 7.9 (Motilin Receptor)<sup>[1]</sup>.

## In Vitro

Camicinal hydrochloride (GSK962040 hydrochloride) had no significant activity at a range of other receptors (including ghrelin), ion channels and enzymes. In rabbit gastric antrum, Camicinal hydrochloride (GSK962040 hydrochloride) 300 nmol L<sup>-1</sup>-10 μmol L<sup>-1</sup> caused a prolonged facilitation of the amplitude of cholinergically mediated contractions, to a maximum of 248 ± 47% at 3 μmol L<sup>-1</sup>. The pEC<sub>50</sub> values for motilin, erythromycin and Camicinal hydrochloride (GSK962040 hydrochloride) were, respectively, 10.4 ± 0.01 (n = 770), 7.3 ± 0.29 (n = 4) and 7.9 ± 0.09 (n = 17) [1]. Camicinal hydrochloride (GSK962040 hydrochloride) activated the dog motilin receptor (pEC<sub>50</sub> 5.79; intrinsic activity 0.72, compared with [Nle13]-motilin) [2]. Camicinal hydrochloride (GSK962040 hydrochloride) was preferred because its initial IC<sub>50</sub> values at CYP3A4 were significantly higher than our preferred threshold of 10 μM [3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

Camicinal (GSK962040) (5 mg free base kg<sup>-1</sup>) also produced an increase in total faecal weight over the 2-h postdose period (21.2 ± 4.5 g; P < 0.05) [1]. Camicinal (GSK962040) induced phasic contractions, the duration of which was dose-related (48 and 173 min for 3 and 6 mg kg<sup>-1</sup>), driven by mean plasma concentrations >1.14 μmol L<sup>-1</sup>. After the effects of Camicinal (GSK962040) faded, migrating motor complex (MMC) activity returned. Migrating motor complex restoration was unaffected by 3 mg kg<sup>-1</sup> Camicinal (GSK962040) but at 6 mg kg<sup>-1</sup>, MMCs returned 253 min after dosing, compared with 101 min after saline (n = 5 each) [2]. The oral bioavailability (F<sub>po</sub>) of Camicinal (GSK962040) was found to be 48 (13%). Camicinal (GSK962040) shows a long lasting effect (T<sub>1/2</sub>) 46.9 (5.0 min at 3 μM) when compared with the short-lived effect of [Nle13]motilin (T<sub>1/2</sub>) 11.4 (1.5 min at 0.3 μM) [3]. Camicinal (GSK962040) strongly facilitated cholinergic activity in the antrum, with lower activity in fundus and small intestine only [4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Chromatographia. 2017, 80(8), 12571262.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Sanger, G.J., et al., GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. *Neurogastroenterol Motil*, 2009. 21(6): p. 657-64, e30-1.
- [2]. Leming, S., et al., GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. *Neurogastroenterol Motil*, 2011. 23(10): p. 958-e410.
- [3]. Westaway, S.M., et al., Discovery of N-(3-fluorophenyl)-1-[(4-[[[(3S)-3-methyl-1-piperazinyl]methyl]phenyl]acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate. *J Med Chem*, 2009. 52(4): p. 1180-9.
- [4]. Broad, J., et al., Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. *Br J Pharmacol*, 2012. 167(4): p. 763-74.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA